News

Lisa Arthurs, VP, trade, Two Labs, discusses a roundtable discussing women in trade as well as empowering future leaders.

Is this level of involvement with HRSNs associated with higher burnout?

This bucket of Pharma Commerce coverage is highly powered by digital solutions.

Pharma Commerce was on the road extensively throughout 2024, and plenty of insight was gathered along the way.

A dive into the top articles in this sector making waves this year.

Check out our top five most engaged social media posts from the year 2024.

The latest in container tech and temperature-monitoring truly powered the content.

The Drug Supply Chain Security Act was a major coverage area for Pharma Commerce in 2024.

Jon Hamrick, partner, Curatio Scientia Advisors, discusses upcoming industry challenges at this year's Trade & Channel Strategies Conference in Philadelphia.

Bill Trombetta, PhD, professor, healthcare strategy, marketing, St. Joseph's University, discusses the difference between return on invested capital in pharma compared to other organizations.

As a result, the provider increases its involvement in the country’s pharma sector.

A cohort study explores the connection between the two, along with the impact of educational attainment on this relationship.

Bill Trombetta, PhD, professor, healthcare strategy, marketing, St. Joseph's University, discusses observations in enterprise value growth and enterprise value-to-sales ratios among top biopharmaceutical companies.

Vibhu Tewary offers insight on this market segment, including a behind-the-scenes of what goes into designing a report.

Cheryl Allen, BS Pharm, MBA, founding partner, Curatio Scientia Advisors, discusses "Enhancing Patient Access and Support Through Technology: A Comprehensive Assessment," and upcoming industry challenges.

The 430,000 square-foot finished production facility will house multiple product types within the rare disease sector, including hemophilia.

A panel examines the gross-to-net bubble across various product mixes, how pricing impacts market access, and more.

Kevin O’Meara discusses how patient service teams influence adherence from Direct-to-Patient models.

Bill Trombetta, PhD, professor, healthcare strategy, marketing, St. Joseph's University, discusses the breakout session at Trade & Channel Strategies in Philadelphia.

A session provides considerations for manufacturers during development, rollouts, and implementation, specifically as it pertains to the HSSP perspective.

Kevin O’Meara discusses Patient-Cetric 3.0 breakout session and the challenges of drug manufactures implementing Direct-to-Patient models.

A session investigates the drivers of these shortages and ways to mitigate them.

Breakout session explores how direct-to-patient models shorten the time to diagnosis and therapy to improve patient outcomes.

A case study explores a way to potentially transform commercial organizations, while driving revenue growth.

A panel uncovers how distribution channels are aligning commercialization efforts.

Conference keynote speech examines the industry’s critical developments of 2024 and offers a strategic outlook for next year.

A cohort study of cancer drugs analyzes where the priorities of pricing policies should lie.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Joe Lipari, director of product management, Systech, predicts the probability that these DSCSA compliance deadlines put forth by the FDA will be met.